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Abstract
Haspin is a serine/threonine kinase required for completion of normal mitosis that is highly
expressed during cell proliferation, including in a number of neoplasms. Consequently, it has
emerged as a potential therapeutic target in oncology. A high throughput screen of approximately
140,000 compounds identified an acridine analog as a potent haspin kinase inhibitor. Profiling
against a panel of 270 kinases revealed that the compound also exhibited potent inhibitory activity
for DYRK2, another serine/threonine kinase. An optimization study of the acridine series revealed
that the structure–activity relationship (SAR) of the acridine series for haspin and DYRK2
inhibition had many similarities. However, several structural differences were noted that allowed
generation of a potent haspin kinase inhibitor (33, IC50 <60 nM) with 180-fold selectivity over
DYRK2. In addition, a moderately potent DYRK2 inhibitor (41, IC50 <400 nM) with a 5.4-fold
selectivity over haspin was also identified.
Keywords
Haspin; DYRK2; Kinase; Inhibitor; Oncology; Structure–activity relationship; Acridine
Haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase), also know as Gsg2 (Germ
Cell-Specific Gene-2),1 is a serine/threonine kinase expressed in a variety of tissues (e.g.,
testis, bone narrow, thymus, and spleen) and in proliferating cells.2 It is also highly
expressed in a number of neoplasms, including Burkitt’s lymphoma3 and diffuse large B cell
lymphomas.4 Haspin’s kinase activity functions during mitosis, where it has been shown to
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phosphorylate histone H3 at Thr-3 (H3T3).5,6 This phosphorylation begins in G2/early
prophase, becomes maximal during prometaphase/metaphase and then diminishes during
anaphase.5,7 Depletion of haspin by RNA interference significantly reduces H3 Thr-3
phosphorylation in cells and prevents normal completion of mitosis.5,8,9
Human haspin, consisting of 798-amino acids, contains a C-terminal kinase domain that is a
divergent member of the eukaryotic protein kinase (ePK) superfamily.10,11 Sequence
comparisons and recent crystal structures reveal that haspin contains a number of structural
differences from other ePKs, particularly in the C-terminal lobe of the kinase domain. For
example, the highly conserved DFG motif involved in ATP binding and the APE motif
involved in stabilizing the activation loop in many ePKs are altered. Haspin adopts a
constitutively active conformation and conserved serine, threonine and tyrosine residues are
absent from its activation loop.10,11
DYRKs (Dual-specificity Tyrosine-regulated Kinases) belong to the CMGC family of ePKs
and contain a conserved kinase domain and adjacent N-terminal DYRK homology box. This
group of kinases can be further divided into class 1 kinases (DYRK1A and 1B) that have an
N-terminal nuclear localization signal and a C-terminal PEST region and class 2 kinases
(DYRK2, 3, and 4), which lack these motifs and are predominantly cytosolic. Although
DYRKs phosphorylate substrates on serine or threonine residues, their activity depends
upon autophosphorylation of an essential activation loop tyrosine during synthesis.12
DYRKs appear to contribute to regulation of an array of signaling pathways, including
NFAT signaling in the brain and immune system, Hedgehog signaling, caspase activity
during apoptosis, cell cycle progression and mitosis, and p53 activation in response to DNA
damage.13–16
In order to study the role of haspin’s kinase activity in mitosis (and other cellular processes)
and its potential role in cancer, we sought to identify and optimize inhibitors. Utilizing a
recently developed time-resolved fluorescence resonance energy transfer (TR-FRET) high
throughput screening (HTS) assay with histone H3 peptide as substrate and a europium-
labeled phosphospecific monoclonal antibody for detecting phosphorylated substrate
(H3T3ph),17 the acridine derivative 1 was discovered as a potent inhibitor (Fig. 1; IC50 =
0.010 μM). Kinase profiling of 1 revealed potent DYRK2 inhibitory activity as well. Herein,
we describe the structure–activity relationship (SAR) of the acridine series for both haspin
and DYRK2 inhibition.
The synthesis of many of the acridine analogs was accomplished using the procedure
outlined in Scheme 1. 2-Bromobenzoic acids 2 were coupled to anilines 3 using a copper-
mediated procedure to give 4.18 Cyclization of 4 to 9-chloroacridines 5 was accomplished
using phosphorus oxychloride. Treatment of 5 with P4S10 in the presence of DMPU gave 6.
Alternatively, acid 4 was cyclized to ketone 7 in the presence of polyphosphoric acid (PPA),
which was subsequently treated with Lawesson’s reagent with microwave (MW) heating at
110 °C to produce 6.19 The thioketone 6 could be alkylated with various amino-protected
alkylbromides (BrCH2(CH2)nY; Y = NHBoc, NMeBoc, or NPhthalimide) in the presence of
base (KOH) and the phase-transfer catalyst tetrabutylammonium iodide (TBAI) in a mixture
of toluene and water to give 8. Boc-protected analogs of 8 (Y = NHBoc or NMeBoc) upon
treatment of 4 N HCl in a mixture of 1,4-dioxane and methanol gave 9 (Z = NH2 or NHMe).
Alternatively for analogs of 9 with Z = NH2, they could also be prepared directly from 6 via
alkylation.
Acridine analogs where the alkylamine groups were connected through an O or NH were
prepared according to the procedure illustrated in Scheme 2. Ketone 10 was converted to 11
as previously described. Then a nucleophilic aromatic substitution with a mono-N-protected
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diamine followed by removal of the protecting group gave 12. Ketone 10 was also alkylated
with N-Boc-protected 1-amino-3-bromopropane in the presence of KOH and phase-transfer
catalyst (i.e., TBAI) followed by de-protection to give 13.
Acridine analogs where the alkylamine group was connected through a methylene were
prepared using the method described in Scheme 3. Diphenylamine derivative 14 was
condensed with acetic acid to give acridine analog 15.20 The methyl substituent in the 9-
position was oxidized with selenium dioxide to give aldehyde 16.21 Addition of the anion of
an N-Boc-protected alkyne gave alcohol 17. Exposure of 17 to reducing conditions (Pd/C
and Et3SiH) resulted in concomitant reduction of the alkyne and alcohol. Finally, removal of
the protecting group on the amine yielded 18.
The synthesis of a tetrahydroacridine analog is outlined in Scheme 4. β-Ketoester 19 was
allowed to react with 4-anisidine, 20, to produce 21. Cyclization of 21 in sulfuric acid gave
ketone 22. This material was converted to the corresponding thioketone 23. Alkylation with
1-amino-3-bromopropane hydrobromide gave 24.
Finally, a 2-phenylquinoline analog was synthesized accord to the procedure outlined in
Scheme 5. The acetophenone derivative 25 was coupled with benzamide in the presence of a
catalytic amount of CuI to give 26.22 Base-mediated cyclization of 26 gave 27. Conversion
of this material to the thiol analog 28 was accomplished with Lawesson’s reagent. Then
alkylation and de-protection as previously described for other analogs yielded 29.
Compound 1 was initially profiled for functional inhibitory activity against a panel of two
hundred and seventy kinases at 10 μM. The results demonstrated that this compound was
quite selective and only inhibited ten of the other kinases by ≥90% (Supplementary Table
S1 and Figure S1).23,24 IC50 values were determined for these kinases (Table 1), with only
five being potently inhibited (IC50 <1 μM). DYRK2 was the most sensitive of these kinases
(IC50 = 2 nM).23,25
For the SAR study, human haspin kinase inhibitory activity of the various compounds was
evaluated using the same assay utilized for the HTS, except in the presence of varying test
compound concentrations.17 DYRK2 kinase inhibitory activity was measured by 33P-
incorporation into Woodtide peptide substrate in the presence of human DYRK2 containing
an N-terminal GST-fusion protein and γ33P-ATP.23
Only one of the methoxys in 1 appears necessary for potent haspin inhibition. When both of
the methoxys were removed (30) inhibitory activity was dramatically reduced (Table 2).
However, when only one of the methoxys was removed (31) or replaced with a methyl (32)
or chlorine (33) potent activity (IC50 <100 nM) was retained. The methoxy substituents of 1
could also be replaced with hydroxyls (34). Interestingly, transposition of the 7-methoxy to
the 3-position (35) resulted in loss of activity. However, the 2-methoxy-3-chloro analog (36)
was still quite active. The three aromatic rings that comprise the acridine also appeared
necessary. Both 24 and 29 lacked haspin inhibitory activity. Next, the tether length between
the thioether at the 9-position of the acridine and the primary amine was examined.
Truncation (37) resulted in reduced activity, while addition of another methylene unit (38)
had only a minimal impact on potency. Next, the contribution of the amine was examined. A
secondary amine (39) was equally potent and a tertiary amine (40) only resulted in a slight
decrease in activity. However, incorporation of the nitrogen into a phthalimide (41 and 42)
resulted in a significant loss of activity. Finally, the thioether was examined (Table 3).
Replacement of the thioether with an amine (12) or ether (13) was detrimental. But
replacement of the sulfur with a methylene (18) retained potent inhibitory activity.
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The SAR for DYRK2 inhibition had many similarities to that observed for haspin inhibition
with some notable exceptions. Both methoxy groups appear to be necessary for DYRK2
inhibitory activity. For example, removal of both methoxy groups (30) was very detrimental,
while removal of one methoxy (31) still resulted in a significant erosion of potency.
Likewise, replacement of one methoxy with a methyl (32) or a chlorine atom (33) was not as
tolerated compared to the results observed for haspin inhibition. Transposition of the 7-
methoxy to the 3-position (35) also lead to loss in activity. Similarly, and unlike in the
haspin SAR, removal of the 7-methoxy and addition of a 3-chloro group (36) was not
tolerated for DYRK2 inhibition. The three aromatic rings that comprise the acridine also
appear necessary for DYRK2 inhibition, with both 24 and 29 lacking activity. The effect of
the tether length between the thioether at the 9-position of the acridine and the primary
amine (37 and 38) was the same as previously observed for haspin inhibition. For DYRK2
inhibition the primary amine was better than secondary (39) or tertiary (40) amines.
Interestingly, incorporation of the nitrogen into a phthalimide resulted in a less dramatic
impact on DYRK2 inhibition compared to haspin and provided a moderately potent analog
(41) that was 5.4-fold selective for DYRK2 verses haspin. Similar to the observations made
with haspin inhibition, replacement of the thioether with an amine (12) or ether (13) was
detrimental to DYRK2 inhibition, while replacement of the sulfur with a methylene (18) was
tolerated, albeit with a fivefold reduction in potency.
In conclusion, a SAR study of the acridine derivative 1, identified utilizing a recently
developed HTS assay, was conducted for both haspin and DYRK2 inhibition. The study
revealed that several structural features of 1, such as the three acridine aromatic rings, the
presence of one or both methoxy groups, a three or four methylene tether between the
thioether and the acridine, and a thioether or CH2 (but not an amine or ether) link to the
acridine were necessary for both haspin and DYRK2 inhibition. However, several structural
differences were noted that allowed generation of a potent haspin kinase inhibitor
LDN-209929 (33, IC50 <60 nM) with 180-fold selectivity verses DYRK2. In addition, a
moderately potent DYRK2 inhibitor LDN-211848 (41, IC50 <400 nM) with a 5.4-fold
selectivity verses haspin was also identified. Additional optimization of the acridine series,
potentially utilizing co-crystallization of these inhibitors with haspin and DYRK2, might
provide more potent and selective inhibitors for both kinases. In addition, these inhibitors
will serve as valuable molecular probes to study the cellular functions of these kinases and
their potential roles in various diseases.
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Figure 1.
Haspin inhibitor identified by HTS. Also shown is the numbering system for acridines.
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Scheme 1.
Reagents and conditions: (a) Cu, K2CO3, pentanol, 110 °C; (b) POCl3, 120 °C; (c) DMPU,
P4S10, 95 °C; (d) PPA, 110 °C; (e) Lawesson’s reagent, THF, MW at 110 °C; (f)
BrCH2(CH2)nY, KOH, TBAI (cat.), toluene, H2O, 110 °C; (g) BrCH2(CH2)nNH2·HBr,
phenol, 80 °C; (h) 4 N HCl in 1,4-dioxane, MeOH, rt.
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Scheme 2.
Reagents and conditions: (a) POCl3, 120 °C; (b) NH2(CH2)3NHBoc; (c) 4 N HCl in 1,4-
dioxane, MeOH, rt; (d) Br(CH2)3NHBoc, KOH, TBAI (cat.), toluene, H2O,
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Scheme 3.
Reagents and conditions: (a) InCl3, AcOH, MW at 230 °C; (b) SeO2, 1,4-dioxane, 80 °C; (c)
HC≡CCH2NHBoc, n-BuLi, THF, −78 °C; (d) Pd/C, Et3SiH; (e) 4 N HCl in 1,4-dioxane,
MeOH, rt.
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Scheme 4.
Reagents and conditions: (a) POCl3, cat. PTSA, 120 °C; (b) H2SO4, 120 °C; (c) DMPU,
P4S10, 95 °C; (d) Br(CH2)3NH2·HBr, phenol, 80 °C.
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Scheme 5.
Reagents and conditions: (a) PhC(=O)NH2, 10 mol % CuI, (MeNHCH2)2, K2CO3, toluene,
170 °C; (b) NaOH, 1,4-dioxane, 110 °C; (c) Lawesson’s reagent, THF, MW at 150 °C; (d)
Br(CH2)3NHBoc, KOH, TBAI (cat.), toluene, H2O, 110 °C; (e) 4 N HCl in 1,4-dioxane,
MeOH, rt.
Cuny et al. Page 11
Bioorg Med Chem Lett. Author manuscript; available in PMC 2011 June 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Cuny et al. Page 12
Table 1
IC50 determinations for 1 against profile panel kinases with ≥90% inhibition at 10 μM
Kinase IC50 (μM)
TRKB 91
CLK1 0.21
DYRK1A 0.10
DYRK2 0.002
DYRK3 0.019
ROS 1.6
HIPK1 1.4
HIPK2 1.3
PIM1 0.72
PIM2 56
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Table 3
IC50 determinations for haspin and DYRK2 kinase inhibition23
Compd X Haspin IC50 (μM) DYRK2 IC50 (μM)
12 NH 1.7 6.5
13 O NA NA
18 CH2 0.025 0.24
NA: Not active at 20 μM.
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